Singapore has emerged as Asia’s preeminent node for the biomedical science industry. The sector — encompassing biopharmaceuticals and medical technology — is vital to the nation's economy. In 2023, it contributed 2.6% to Singapore's GDP, manufacturing products valued at nearly $38 billion for global markets.

The country’s diverse and established biopharmaceutical sector is a result of several factors, including a pro-business environment and infrastructure support. Through its dedicated estates like Tuas Biomedical Park and Biopolis, JTC has enabled both global pharmaceutical giants and cutting-edge biotech firms to call Singapore home. 

From master planning to modular build-outs, JTC provides far more than infrastructure. In Tuas Biomedical Park, for example, ready-built facilities serve the manufacturing needs of some of the world’s largest pharmaceutical firms. At one-north’s Biopolis, JTC fosters a research and discovery ecosystem where public and private institutions intersect.

Here is a showcase of the names in biomedical science who have anchored themselves in Singapore, many within JTC-developed spaces. Together, they reflect the breadth and depth of the nation's biomedical science landscape.

AbbVie
A global biopharmaceutical company with a focus on immunology and oncology, AbbVie has announced a US$223 million (around $301 million) expansion of its manufacturing facility in Singapore. The investment will create more than 100 jobs and increase production capacity by 24,000 litres of biologics drug-substance, supporting both existing products and new immunology and oncology drugs in AbbVie's pipeline.

AstraZeneca
UK-based pharmaceutical giant AstraZeneca has announced that it is building a US$1.9 billion (around $2.5 billion) facility in Singapore. Targeted to be operationally ready by 2029, AstraZeneca plans to establish the world’s first end-to-end antibody drug conjugate (ADC) manufacturing plant in Singapore to enhance the global supply of its ADC portfolio.

bioMérieux
Global in vitro diagnostics leader bioMérieux provides solutions for detecting infectious diseases and antimicrobial resistance. From its Singapore regional base, the company advances molecular diagnostics and point-of-care testing through strategic collaborations and acquisitions. In January 2025, bioMerieux announced that it has entered into an agreement to acquire SpinChip Diagnostics ASA, a privately held Norwegian diagnostics company that has developed an immunoassay diagnostics platform.

BioNTech
BioNTech is pioneering novel therapies for cancer and other serious diseases. The facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for Southeast Asia to address potential pandemic threats 

Bruker Singapore 
Bruker, a global leader in scientific instrumentation, provides advanced tools for molecular research, materials analysis, and diagnostics. The company continues to expand its clinical diagnostics capabilities, particularly in mass spectrometry-based assays through strategic partnerships and acquisitions. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmBH, a Munich-based provider of mass spectrometry-based diagnostic assay kits for therapeutic drug monitoring. This collaboration aims to enhance Bruker's capabilities in small molecule clinical diagnostic assays.

GSK 
One of the earliest multinational pharma companies to establish a presence in Singapore, GSK invested $343 million in 2023 to expand its manufacturing facility here to produce Hepatitis B antigen, a key component in five GSK vaccines globally. The expansion also aimed to create 100 jobs and use advanced technologies and paperless systems to ensure consistent product quality.

Hoya
Hoya Medical Singapore Pte Ltd (HMS) serves as the global headquarters of Hoya Surgical Optics (HSO), which is one of the fastest growing intra-ocular (IOL) lens manufacturer in the world.  HMS’ global HQ and Technical Centre, which is HSO's first R&D centre outside of Japan, is in Biopolis. 

Illumina
Illumina is an industry leader in the R&D and manufacturing of market-integrated systems for the analysis of genetic variations and biological functions. Its solutions aim to pioneer advancements in oncology, genetics, infectious diseases, and productive healthcare. Some of its products include DNA-sequencing machines and microarray tools which have applications in genome-related analyses and medical diagnoses. Illumina operates their commercial HQ in Biopolis and has been a tenant at Biopolis since 2012. 

Life Science Incubator
Life Science Incubator (LSI) builds and operates world-class co-working laboratories for bio-, med-, and foodtech companies to develop and scale. Following the success of their first laboratory at the German Centre in 2021, LSI has expanded to one-north’s Elementum through a collaboration with Ho Bee Land. The Elementum facility opened in early 2025 and caters to the growing demand for high-quality lab spaces, supporting startups, entrepreneurs, and multinational firms. Beyond workspace, LSI connects companies with potential partners and supports local entrepreneurship through accelerator and academic partnerships.

MediSix Therapeutics
Founded in 2016 by Professor Dario Campana, an expert in cell therapy and creator of the first anti-CD19 CAR, MediSix Therapeutics develops and leverages unique proprietary technologies to build a pipeline of research products that aims to overcome the challenges in cancer and autoimmune disease treatments. Headquartered at 11 Biopolis Way, MediSix also maintains a presence in Boston, USA. The company continues to expand its pipeline through collaborations, including a partnership with Twist Bioscience to discover novel antibodies for CAR T-cell therapies.
 
MiRXES
Headquartered in Singapore, MiRXES is a home-grown biotechnology company that specialises in q-PCR based technology, and the development of micro-RNA enabled molecular diagnostics. Today, it is a leading developer for RNA-powered tests for the early detection of diseases.   

Novartis
To address demand in Asia, the Swiss pharmaceutical giant is investing US$256 million (about $331 million) to expand its biopharmaceutical manufacturing site in Singapore. Novartis's expanded facility will leverage digital automation to increase productivity and enhance workforce skills, while focusing on therapeutic antibody production for global patient care.

NovogeneAIT Genomics Singapore
NovogeneAIT is a multi-omics services and solutions provider headquartered in Singapore. Established in October 2016 as a joint venture between China's Novogene and Singapore's AITbiotech, the company has rapidly become one of Southeast Asia's largest next-generation sequencing (NGS) providers. It advances genomic research through its Singapore sequencing centre.
Under Singapore's National Precision Medicine (NPM) initiative, NovogeneAIT was appointed as the sequencing service provider for sequencing 10,000 Singaporean genomes using Oxford Nanopore technology.

Peptobiotics 
Peptobiotics, founded in 2020, is a Singapore-based agritech startup developing sustainable alternatives to antibiotics in animal agriculture. The company creates recombinant antimicrobial peptides (AMPs) using synthetic biology to improve animal health without risking antibiotic resistance.Following a US$6.2 million Series A funding round led by Hatch Blue's Blue Revolution Fund in April 2024, Peptobiotics aims to scale production and commercialize its AMP technology.

Pfizer
A long-time investor in Singapore, Pfizer’s facility in Tuas produces APIs for drugs treating cardiovascular and infectious diseases. It has expanded its manufacturing footprint in Singapore with a $1 billion state-of-the-art facility, which spans 429,000sqft and will produce various small molecule APIs for oncology, pain, and antibiotic medicines. Additionally, the facility has achieved a Green Mark gold certification, a Singapore accreditation for environmental sustainability.

Sanofi
Sanofi’s facility in Singapore is the most advanced in its global manufacturing network, incorporating extensive Industry 4.0 technologies. It also becomes the industry’s first commercial facility to use a single-use technology platform for large-scale vaccine production, reflecting its commitment to Industry 4.0.

Singapore Sciences 
Founded in 2014, Singapore Sciences develops research-based healthcare solutions for chronic diseases, focusing on endocrinology, immunology, and oncology. The company also researches non-invasive cataract treatments. Singapore sciences is also conducting research into non-invasive therapeutic options for cataract management.

STA Pharmaceutical Singapore 
WuXi AppTec is building a new R&D and manufacturing site in Tuas Biomedical Park. Projected to start operations in 2027, the site will have seven plants, providing active pharmaceutical ingredient (API) R&D and manufacturing services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates. Using advanced green chemistry technologies, the site enhances industrial sustainability while supporting local community development. It will also integrate with WuXi AppTec's global network across Asia, Europe, and North America.

Roquette
Roquette is a global family-owned leader in specialty food ingredients and pharmaceutical excipients. It develops plant-based solutions from corn, wheat, potatoes and peas for pharmaceutical, nutrition and food industries. Roquette is also expanding the global footprint of its pharmaceutical business via partnerships and acquisitions, including that of Qualicaps and IFF Pharma Solutions. 

WuXi Biologics Singapore
WuXi Biologics recently broke ground on its Contract Research, Development and Manufacturing Organisation (CRDMO) centre in Singapore. The US$1.4 billion (about $2 billion) investment will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing services upon completion. The site combines WuXi Biologics' proprietary platforms with industry-leading technologies, delivering efficient client services while embracing sustainable design and digital innovation.